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Abstract Developmental neurotoxicity (DNT) and many
forms of reproductive toxicity (RT) often manifest them-
selves in functional deficits that are not necessarily based
on cell death, but rather on minor changes relating to cell
differentiation or communication. The fields of DNT/RT
would greatly benefit from in vitro tests that allow the
identification of toxicant-induced changes of the cellular
proteostasis, or of its underlying transcriptome network.
Therefore, the ‘human embryonic stem cell (hESC)-
derived novel alternative test systems (ESNATS)’ Euro-
pean commission research project established RT tests
based on defined differentiation protocols of hESC and
their progeny. Valproic acid (VPA) and methylmercury
(MeHg) were used as positive control compounds to
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address the following fundamental questions: (1) Does
transcriptome analysis allow discrimination of the two
compounds? (2) How does analysis of enriched transcrip-
tion factor binding sites (TFBS) and of individual probe
sets (PS) distinguish between test systems? (3) Can batch
effects be controlled? (4) How many DNA microarrays are
needed? (5) Is the highest non-cytotoxic concentration
optimal and relevant for the study of transcriptome chan-
ges? VPA triggered vast transcriptional changes, whereas
MeHg altered fewer transcripts. To attenuate batch effects,
analysis has been focused on the 500 PS with highest
variability. The test systems differed significantly in their
responses (\20 % overlap). Moreover, within one test
system, little overlap between the PS changed by the two
compounds has been observed. However, using TFBS
enrichment, a relatively large ‘common response’ to VPA
and MeHg could be distinguished from ‘compound-spe-
cific’ responses. In conclusion, the ESNATS assay battery
allows classification of human DNT/RT toxicants on the
basis of their transcriptome profiles.
Keywords Methylmercury  Valproic acid 
Transcription factor  Reproductive toxicity 
Alternative testing strategies
Abbreviations
PS Probe sets
DMA DNA microarray
BMC Benchmark concentration
TFBS Transcription factor binding site
GO Gene ontology
Introduction
Reproductive toxicity (RT) testing is one of the technically
most challenging fields of toxicology, and there is a huge
demand for more cost-effective, faster, and more accurate
assays. RT may be caused by chemicals, drugs, pesticides
and other compounds that interfere with biological pro-
cesses essential for reproduction, and it is therefore of large
societal concern. It has been estimated that up to 50 % of
the animals used for testing in the context of REACH will
be required to evaluate RT (Seiler et al. 2011). Currently,
this type of safety assessment comprises evaluation of
chemical effects on spermatogenesis, oogenesis or the
fertilization process. Another large subfield deals with the
disturbances of embryo–foetal development and is gener-
ally called developmental toxicity (DT) testing.
In the area of RT testing, evaluation of a single com-
pound requires hundreds of animals. If testing of nervous
system development and long-term effects are included,
even thousands of rats/rabbits are required. Animal testing,
for example, following OECD test guidelines 414 (2-gen-
eration reproduction), 426 (developmental neurotoxicity
(DNT)) or others, often only gives indirect indications of
toxicity such as changed numbers of embryo–foetal death,
altered foetal weight or the development of anatomical or
behavioural abnormalities. To significantly reduce the use
of animals and to get further mechanistic insights, in vitro
systems modelling critical parts of the foetal development
are being explored as alternatives (Adler et al. 2011;
Basketter et al. 2012); for instance, the development of
initial germ layers from pluripotent cells, and the specifi-
cation of organ systems such as the central nervous system
(CNS) are such critical parts of the development.
The CNS is considered to be one of the most frequent
targets of systemic toxicity, with the developing nervous
system being particularly susceptible (Klaassen 2010; van
Thriel et al. 2012). This susceptibility to DNT is due to a
finely orchestrated sequence of complex biological pro-
cesses, such as proliferation, migration, apoptosis, differ-
entiation, patterning, neurite outgrowth, synaptogenesis,
myelination and neurotransmitter synthesis, which are all
targets of numerous toxic chemicals (Kadereit et al. 2012).
Despite its high relevance, DNT is one of the least studied
forms of toxicity (Kadereit et al. 2012; Makris et al. 2009).
It is also particularly difficult to study, because DNT is not
necessarily caused by cell death. In fact, chemically
induced changes in the proportions of neural cells, posi-
tioning or connectivity may be sufficient to cause DNT
(Kadereit et al. 2012; Kuegler et al. 2010). Currently, DNT
is tested according to OECD TG 426, which requires ani-
mals to be exposed during gestation and lactation, and the
resulting offspring to be analysed for gross neurologic and
behavioural abnormalities. However, this complex in vivo
test system is too laborious and expensive to allow all the
testing needed to provide hazard information for thousands
of untested chemicals.
To bridge this gap, embryonic stem cell (ESC)-based
systems are currently being developed (Kuegler et al. 2012;
Leist et al. 2008a; Weng et al. 2012; Zimmer et al. 2012).
These systems recapitulate early neuronal development
in vitro, including neurulation, patterning, neurogenesis
and gliogenesis. In the present study, five human ESC
(hESC)-based in vitro systems, named here after the
developing institutions, have been employed. They reca-
pitulate different phases of early tissue specification and
neural development (Fig. 1). UKK recapitulates the multi-
lineage differentiation of hESC into ecto-, meso- and
endoderm (Jagtap et al. 2011; Meganathan et al. 2012).
UKN1 models the stage of neuroectodermal induction that
results in the formation of neural ectodermal progenitor
cells (NEP) (Balmer et al. 2012; Chambers et al. 2009).
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JRC reproduces the neural tube formation during early
neurogenesis by the formation of neural rosettes (Stum-
mann et al. 2009). UNIGE models the transition from
neural precursor cells to mature neurons, showing mor-
phological signs of neural differentiation, including neurite
extensions. UKN4 already starts with neuronally commit-
ted precursor cells that undergo the maturation towards
post-mitotic neurons with neurites. These cells were not
derived from hESC but from a human foetal brain (Scholz
et al. 2011; Stiegler et al. 2011).
Differentiating murine ESCs show similar waves of
gene expression changes as observed during murine
embryonic development in vivo (Barberi et al. 2003;
Gaspar et al. 2012; Kadereit et al. 2012; Zimmer et al.
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Fig. 1 Overview over the test
systems’ treatment protocols
used for microarray analysis.
The five test systems cover
different periods and processes
relevant to early embryonic/
neuronal development, as
indicated to the left. The time
arrows indicate when cells were
re-plated, medium was
exchanged, toxicants were
added and when analysis was
performed. Additional
information is presented below
each test system on the type of
coating and the medium used in
different experimental phases
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2011a, b). Such information is not available for early
human development, but it is generally assumed by anal-
ogy that hESC would reproduce normal human tissue dif-
ferentiation (Leist et al. 2008a). Under this condition,
transcriptome analysis, including bioinformatic processing
of the data, appears as an attractive method to detect per-
turbations caused by chemicals in the normal wave-like
expression patterns in hESC differentiation systems.
Moreover, alterations in the proportions of cell types, as a
consequence of exposure to test compounds, should be
detectable by DNA microarrays (DMA), as shown earlier
for other systems (Schmidt et al. 2008, 2012). The treat-
ment period for each test system was chosen according to
previously described effects (Fig. 1). For example, in
UKN4, neurite outgrowth starts on day of differentiation
(DoD) 2 and can be measured at DoD3 (Stiegler et al.
2011). Therefore, DMA analysis was also performed here
under similar incubation conditions. In the same vein, it is
known for UKN1 that changes in gene expression are best
detectable after treatment from DoD 0 to 6 (Balmer et al.
2012) and accordingly transcriptome analysis was done on
DoD6 after 6 days of incubation with test compound.
For test system evaluation, we have chosen valproic acid
(VPA) and methylmercury (MeHg), two model compounds
that trigger RT and DNT in humans and animals (Chen
et al. 2007; Grandjean and Landrigan 2006; Kadereit et al.
2012; Wang et al. 2011). The ability of VPA to cause DNT
has been recognized since the 1970s. VPA is a clinically
used anti-epileptic drug that acts as a reversible modifier of
enzyme activities. It has also been shown to cause neural
tube defects and to trigger large changes of the cellular
transcriptome through the inhibition of histone deacety-
lases (Jergil et al. 2009; Theunissen et al. 2012a; Werler
et al. 2011). MeHg also causes neural tube defects
(Grandjean and Herz 2011; Robinson et al. 2011). How-
ever, the transcriptional changes due to MeHg are more
limited and indirect, as it acts through the unspecific
modification of many different proteins, in addition to
triggering oxidative stress (Aschner et al. 2007). Despite its
unclear mode of action, MeHg is a ‘gold standard’, because
human DNT has been particularly well documented,
mainly due to the catastrophic endemics caused by MeHg-
contaminated food (Bakir et al. 1973; Choi 1989; Davidson
et al. 2004; Ekino et al. 2007; Harada 1995).
The widespread use of transcriptomics endpoints
requires clarification of important technical issues. There-
fore, we addressed here the following questions: (1) Does
DMA analysis allow differentiation between distinct clas-
ses of toxicants and non-toxicants. If yes, (2) how large is
the overlap between the available ESC based test systems
(Fig. 1), and are they all required for the identification of
DNT compounds? (3) How many independent experiments
are needed? (4) At which optimal concentrations should
gene array analyses be performed? The present study
provides unequivocal answers to these questions and will
therefore serve as a basis for further development of RT
assays on the basis of DMA classification algorithms.
Materials and Methods
Chemicals
Valproic acid (VPA), mannitol and methylmercury chlo-
ride (MeHg) were obtained from Sigma. Stocks of VPA
and mannitol were prepared in water. MeHg was initially
dissolved in 10 % ethanol. A concentration of 10 mM
MeHg in this solvent was used as a master stock. For
experiments, the MeHg solution was pre-diluted 1:1000 in
water (final solvent concentration 0.1 %) and used as the
stock for further dilution with medium. The highest test
solvent concentration used in this study (at 1.5 lM MeHg)
was 0.0015 % ethanol.
Cell culture maintenance and experimental set-up
UKK
NIH-registered H9 human embryonic stem cells (WA09,
WiCell Research Institute, Madison, WI, USA) were cul-
tured in DMEM-F12, 20 % KO serum replacement, 1 %
non-essential amino acids, penicillin (100 units/ml),
streptomycin (100 lg/ml) and 0.1 mM b-mercaptoethanol
supplemented with 4 ng/ml human recombinant basic
fibroblast growth factor (bFGF) at 37 C and 5 % CO2. The
undifferentiated stem cells (hESCs) were routinely pas-
saged with mechanical dissociation on irradiated mouse
embryonic fibroblasts (MEF). Prior to differentiation, the
cells were maintained for 5 days in 60-mm tissue culture
plates (Nunc, Langenselbold, Germany) coated with a
hESC-qualified matrix (BD Biosciences, California, USA)
in TESR1 medium (Stem Cell Technologies, mTESR1
basal medium ? mTESR1 59 supplement). For multilin-
eage differentiation, embryoid bodies (EBs) were prepared
as described previously (Jagtap et al. 2011) with minor
changes (60–70 clumps were added and bacteriological
plates were not coated with pluronic), and the EBs were
maintained for 14 days on a horizontal shaker with or
without drug treatment. Toxicant exposure was performed
as indicated in Fig. 1.
UKN1
H9 hESCs (as for UKK) were differentiated by dual SMAD
inhibition as described earlier in detail (Balmer et al. 2012;
Chambers et al. 2009; Weng et al. 2012). Briefly, hESCs
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were plated as single cells at a density of 18,000 cells/cm2
in medium previously conditioned for 24 h with mitomycin
C-inactivated mouse embryonic fibroblasts, containing
10 lM ROCK inhibitor Y-27632 and 10 ng/ml bFGF.
Medium was changed daily to conditioned medium con-
taining 10 ng/ml bFGF for 2 days. Differentiation was
initiated 3 days after re-plating on day of differentiation
(DoD) 0 by changing the medium to knockout serum
replacement medium (KSR) (Knockout DMEM with 15 %
knockout serum replacement, 2 mM Glutamax, 0.1 mM
MEM non-essential amino acids and 50 lM beta-mercap-
toethanol) supplemented with 35 ng/ml noggin, 600 nM
dorsomorphin and 10 lM SB-431642. From DoD4
onwards, KSR was replaced stepwise with N2 medium
(DMEM/F12 medium, 1 % Glutamax, 1.55 mg/ml glu-
cose, 0.1 mg/ml apotransferrin, 25 lg/ml insulin, 100 lM
putrescine, 30 nM selenium and 20 nM progesterone),
starting with 25 % N2 medium at DoD4. To assess the
chemical effects on RNA expression, the cells were dif-
ferentiated in the presence or absence of the chemicals
from DoD 0 for 6 days.
JRC
NIH-registered H9 hESCs (WiCell, USA) were cultured
undifferentiated in 60-mm cell culture dishes (TPP, Swit-
zerland) at 37 C and 5 % CO2 on a layer of mitomycin
C-inactivated primary mouse embryonic fibroblasts (pMEF,
CF-1 strain Millipore USA), which were plated at a density
of 15000 cells/cm2, on gelatine-coated dishes in the pres-
ence of the standard maintenance medium for undifferen-
tiated hESCs [DMEM/F12 supplemented with 20 % KO
serum replacement, 1 % non-essential amino acids, 2 mM
glutamine, 0.1 mM b-mercaptoethanol and 4 ng/ml human
recombinant bFGF (all from Invitrogen, USA)]. Cells were
expanded weekly by microdissection and further propa-
gated on a feeder layer. For the differentiation towards early
neuroepithelial precursors, a published protocol was mod-
ified (Stummann et al. 2009). Briefly, intact 6-day-old H9
hESC colonies were detached by 1 mg/ml collagenase
(Invitrogen, USA) treatment and left in suspension culture
dishes for 3 days in hESC maintenance medium without
bFGF to allow the generation of EBs. After this time, EBs
were transferred onto single wells (one EB per well) of
96-well plates coated with 10 lg/ml laminin [in water
(Sigma, USA)] containing neural induction medium
[DMEM/F12 supplemented with 1 % non-essential amino
acids, 1 % N2 supplement, 2 lg/ml heparin (Sigma, USA)
and 20 ng/ml bFGF (unless stated, all from Invitrogen,
USA)]. Cultures were kept for up to 10 days with medium
changes every third day. The attached EBs were observed
daily and by day 10 they formed neural tube–like structures
known as neural rosettes.
UNIGE
For neural differentiation, an aliquot of H9 cells (WA09,
WiCell Research Institute, Madison, WI, USA) was thawed
and cultured in suspension in T75 flasks with N2B27 medium
(Life Technologies). From day 2 to 7, cells were incubated in
N2B27 medium supplemented with 10 lM anti TGF-beta
(Ascent) and 2 lM dorsomorphin (Tocris Bioscience). From
day 8 to 32, medium replacement was performed with N2B27
medium only. On day 33, generated spheres were dissociated
as single cells and cultured in N2B27 medium in poly orni-
thine (PLO) and laminin-coated 6-well plates. On day 36,
cells were detached and frozen in N2B27 medium in different
aliquots. To test neurotoxicity of chemical compounds, an
aliquot was thawed in PLO and laminin-coated 6-well plates.
Cells were cultured in a neuronal differentiation medium (ND
medium) made of NB medium, B-27 supplement, 2 mM
L-Glutamine and penicillin/streptomycin (Life Technologies)
as well as 10 ng/ml BDNF, 10 ng/ml recombinant human
glial cell-derived neurotrophic factor (GDNF) (Chemie
Brunschwig) and 10 lM ROCK inhibitor (Ascent). After
1 day of recovery, cells were incubated with the neurotoxi-
cant in ND medium without ROCK inhibitor for 2 days and
then material was collected for analysis.
UKN4
Lund human mesencephalic cells (LUHMES) were cultured
exactly as described earlier (Scholz et al. 2011; Stiegler et al.
2011). Briefly, cells were maintained in advanced DMEM-F12,
1x ‘N2 supplement’, 2 mM L-glutamine and 40 ng/ml bFGF at
37 C in a humidified 95 % air/5 % CO2 atmosphere on Nun-
clonTM plastic cell culture flasks, coated with 50 ng/ml PLO and
1 lg/ml fibronectin. Proliferating cells were enzymatically dis-
sociated with trypsin (138 mM NaCl, 5.4 mM KCl, 6.9 mM
NaHCO3, 5.6 mM D-Glucose, 0.54 mM EDTA, 0.5 g/l trypsin
from bovine pancreas type-II-S) and passaged every other day.
For differentiation, 8 9 106 LUHMES were seeded into a
T175 flask in proliferation medium and differentiation was
started after 24 h on day 0 (d0), by changing to advanced
DMEM-F12, 19 ‘N2 supplement’, 2 mM L-glutamine, 1 mM
dibutyryl 30,50-cyclic adenosine monophosphate (cAMP),
1 lg/ml tetracycline and 2 ng/ml GDNF. After 2 days of cul-
tivation in culture flasks, cells were trypsinized and seeded onto
PLO/fibronectin-precoated 96-well plates at a cell density of 30
000/well in advanced DMEM-F12, 19 ‘N2 supplement’,
2 mM L-glutamine, 1 lg/ml tetracycline. One hour after re-
plating, cells were exposed to toxicants for 24 h.
Affymetrix gene chip analysis
Analysis was performed as described earlier (Balmer et al.
2012; Jagtap et al. 2011). Briefly, samples from approximately
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5 9 106 cells were collected using RNAprotect reagent from
Qiagen. The RNA was quantified using a NanoDrop N-1000
spectrophotometer (NanoDrop, Wilmington, DE, USA), and
the integrity of RNA was confirmed with a standard sense
automated gel electrophoresis system (Experion, Bio-Rad,
Hercules, CA, USA). The samples were used for transcrip-
tional profiling when the RNA quality indicator (RQI) number
was[8. First-strand cDNA was synthesised from 100 ng total
RNA using an oligo-dT primer with an attached T7 promoter
sequence, followed by the complementary second strand. The
double-stranded cDNA molecule was used for in vitro tran-
scription (IVT, standard Affymetrix procedure) using Gene-
chip 30 IVT Express Kit. During synthesis of the aRNA
(amplified RNA, also commonly referred to as cRNA), a
biotinylated nucleotide analogue was incorporated, which
serves as a label for the message. After amplification, aRNA
was purified with magnetic beads and 15 lg of aRNA was
fragmented with fragmentation buffer as per the manufac-
turer’s instructions. Then, 12.5 lg fragmented aRNA was
hybridised with Affymetrix Human Genome U133 plus 2.0
arrays as per the manufacturer’s instructions. The chips were
placed in a GeneChip Hybridization Oven-645 for 16 h at
60 rpm and 45 C. For staining and washing, Affymetrix HWS
kits were used on a Genechip Fluidics Station-450. For scan-
ning, the Affymetrix Gene-Chip Scanner-3000-7G was used,
and the image and quality control assessments were performed
with Affymetrix GCOS software. All reagents and instruments
were acquired from Affymetrix (Affymetrix, Santa Clara, CA,
USA).The generated CEL files were used for further statistical
analysis. The authors declare that microarray data were pro-
duced according to MIAME guidelines and will be deposited in
ArrayExpress upon acceptance of the manuscript.
Cytotoxicity testing
In order to determine the cytotoxic range of the chemicals to
be tested with the DMA, a resazurin assay was performed in all
test systems. The assay is based on the capability of viable and
healthy cells to reduce resazurin to resorufin, which can be
measured by a colorimetric or fluorimetric shift as described
earlier (Stiegler et al. 2011; Stummann et al. 2009). Exposure
time to chemicals and day of analyses for this endpoint was the
same as for the experimental set-up of the RNA sampling
(Fig. 1). Chemicals were tested at several concentrations.
Each condition was run in technical triplicates in at least three
independent biological experiments. On the day of analysis,
cells were incubated with 10 lg/ml resazurin for 30 min to
1 h at 37 C and 5 % CO2. To determine the background
fluorescence of resazurin itself, a control with only resazurin
in medium was included. Resorufin was measured at a
wavelength of 560E9/590Em with a fluorescence reader. The
mean background fluorescence of resazurin was subtracted
from all experimental data. Further data processing to identify
the lowest non-cytotoxic ‘benchmark concentration’ (BMC)
of the chemicals was done as follows: data from each exper-
iment were normalised to their respective untreated controls
(set as 100 %). The data were then displayed in semiloga-
rithmic plots. Data points were connected by a nonlinear
regression sigmoidal dose–response curve fit. These curves
were averaged, and the average curve was plotted. The BMC
was then determined graphically as the data point on the
average curve corresponding to the 90 % viability value, or as
the last real data point left of this value. The BMC was used as
test concentration for DMA analysis. The ‘lower test con-
centration’ (LOW) was determined by dividing the BMC by a
factor of four.
In vitro–in vivo extrapolation
In vitro–in vivo extrapolation (IVIVE) of toxicity data can be
achieved using physiologically based pharmacokinetic
(PBPK) modelling (Carrier et al. 2001; Forsby and Blaauboer
2007; Louisse et al. 2010; Rotroff et al. 2010; Verwei et al.
2006; Wetmore et al. 2012).The extrapolation is based on the
implicit assumption that equal concentrations at the target site
in vitro and in vivo lead to equal effects. In this project, in vitro
nominal concentrations equivalent to relevant toxic concen-
trations in vivo were determined in two steps. (1) PBPK
modelling was used to simulate systemic concentrations cor-
responding to the lowest dose level at which neurodevelop-
mental effects were observed in rats. The acslX software was
used for the simulations (v3.0.1.6; Aegis Technologies,
Huntsville AL, USA). (2) The unbound fraction may differ
between in vitro and in vivo systems due to differences in
albumin concentrations and lipid fractions between plasma or
extracellular fluid and test medium. The nominal in vitro
concentration Cvitro equivalent to the maximum systemic
concentration in vivo Cpl was derived by correcting for these
differences by:
Cvitro ¼ Cpl 

1  fb;pl
 
 1 þ Kow  VFL;vitro
1 þ Kow  VFL;pl þ fb;pl 
Pvitro
Ppl

where fb,pl is the plasma bound fraction, VFL,pl and
VFL,vitro are the volume fractions of lipids in plasma and
in vitro, Ppl and Pvitro are the concentrations of albumin in
plasma and in vitro (Gulden and Seibert 2003). Supple-
mentary figure S6B shows the lipid content and albumin
concentrations in the test systems and in rat plasma.
IVIVE of MeHg data
The kinetics of MeHg in rats was previously described
using a detailed PBPK model by Carrier et al. (2001). This
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PBPK model was used in the current project to predict
systemic concentrations of MeHg after exposure to dosages
known to result in relevant toxic effects in vivo. A com-
prehensive review of neurodevelopmental toxicity of
MeHg in laboratory animals was published by Castoldi
et al. (2008). The lowest maternal exposures in rat leading
to behavioural and neurophysiological effects in the off-
spring were between 0.01 and 0.05 mg/kg/day from ges-
tation day 6 to 9 (Bornhausen et al. 1980). MeHg
extensively binds to intra- and extracellular proteins by the
formation of cysteine complexes. The MeHg–cysteine
complexes readily pass placental and blood–brain barriers
by facilitated transport (Gray 1995). Maternal and foetal
blood concentrations were found to be similar (Gray
1995).The total blood concentration was therefore assumed
to be available for foetal brain exposure and equated to the
nominal concentration in vitro.
IVIVE of VPA data
A PBPK model for VPA was developed and calibrated
according to data of Binkerd et al. (1988) and Kobayashi
et al. (1991). Model equations and parameterization are
given in the supplemental material (Fig. S6). This model
was used to predict systemic VPA concentrations corre-
sponding to the lowest dose at which neurodevelopmental
effects were observed in rats in vivo. A single intraperi-
toneal dose of VPA in rat dams of 350 mg/kg was found by
Rodier et al. (1996) to cause behavioural and neuromor-
phological effects in the offspring. Oral and intraperitoneal
doses lead to comparable plasma kinetics (Ingram et al.
2000). VPA is known to pass the placental barrier in sev-
eral species; therefore, comparable VPA concentrations were
assumed in maternal and cord plasma. The unbound concen-
tration in plasma was equated to the unbound test medium
concentrations. For the correction of binding, a bound fraction
in plasma of 63 % was used (Loscher 1978).
Statistical analysis of gene array data
The following analyses were performed using the statistical
programming language ‘R-version 2.15.1’ For the nor-
malisation of the entire set of 190 Affymetrix gene
expression arrays, the Robust Multi-array Average (RMA)
algorithm (Irizarry et al. 2003) was used that applies
background correction, log2 transformation, quantile nor-
malisation and a linear model fit to the normalised data to
obtain a value for each probe set (PS) on each array. To
avoid having to re-normalise future-generated data for
comparison with the current data, we used the R package
RefPlus (Harbron et al. 2007) that allows the user to per-
form extrapolation strategies by remembering the normal-
isation parameters. After normalisation, gene expression
for each gene at each concentration was adjusted by
comparing the expression to the corresponding control
array expression, that is, the difference between gene
expressions at each concentration compared to the control
was calculated (paired design).
Differential expression was calculated using the R
package limma (Smyth et al. 2005). Here, the combined
information of the complete set of genes is used by an
empirical Bayes adjustment of the variance estimates of
single genes. This form of a moderated t test is abbreviated
here as ‘Limma t test’. The resulting p values were mul-
tiplicity-adjusted to control the false discovery rate (FDR)
by the Benjamini–Yekutieli procedure. As a result, for each
combination of centre (=test system), compound and con-
centration, a gene list was obtained, with corresponding
estimates for log fold change and p values of the Limma
t test (unadjusted and FDR-adjusted).
Data display algorithms
General test quality control was as described (Leist et al.
2010). Heatmaps were used to visualise matrices of gene
expression values. Colour encodes the magnitude of the
values, ranging from yellow (low) to red (high). Volcano
plots were used to visualise genome-wide differential
expression. Gene wise fold-change values (log2 scale) are
plotted against (unadjusted or FDR-adjusted Limma t test)
significance values (negative log10 scale) on the x-axis and
y-axis, respectively. Principal component analysis (PCA)
plots were used to visualise expression data in two
dimensions, representing the first two principal compo-
nents, that is, the two orthogonal directions of the data with
highest variance. The percentages of the variances covered
are indicated in the figures. The software ‘R - version
2.15.1’ was used for all calculations and display of PCA
and heatmaps (R_Development_Core_Team 2011). The
calculation and display of toxicity curves was done using
GraphPad Prism 5.0 (Graphpad Software, La Jolla, USA).
The Venn diagrams for the comparison of gene expression,
gene ontology (GO) terms and transcription factor binding
sites (TFBS) between test systems were constructed
according to Chow and Rodgers (2005). The size of circles
and areas was chosen proportional to the number of ele-
ments included.
Transcription factor binding site enrichment (TFBSE)
was performed using the PRIMA algorithm (Elkon et al.
2003; http://acgt.cs.tau.ac.il/prima/) provided in the
Expander software suite (version 6.04, (Ulitsky et al.
2010); http://acgt.cs.tau.ac.il/expander/). Lists of signifi-
cant differentially expressed genes with adjusted p value
\0.05 were converted to Entrez IDs (R package hgu133-
plus2.db) and duplicates were removed. The PRIMA
algorithm was run with a p value threshold set to 0.05, no
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multiple testing correction, a background set of all human
genes (provided in the Expander software suite), and using
the TRANSFAC database (8.2) as the data source for
transcription factor binding sites. The PRIMA algorithm
analyses 267 separate TRANSFAC entries. PRIMA results
are presented in tables with TF identifiers provided by
PRIMA and their full names, or the overlap between TF
enrichments for different treatments is shown as Venn
diagrams or as tables [Cytoscape; (Shannon et al. 2003;
Smoot et al. 2011); http://www.cytoscape.org].
For the word clouds of the overrepresented GO groups, a
g:Profiler query (Reimand et al. 2007) was initially made,
and only results from the biological process and pathway
branches were retained. These were viewed as a subgraph
of the whole GO tree. All categories were deleted that were
larger than 1,000 genes and smaller than 50 genes. Then,
connected components from the remaining graph were
identified, and from each of these, the category with the
highest p value was selected. These were ordered by
p value and the top 40 are displayed. When displaying the
categories, the font sizes were first scaled to be propor-
tional to the log10 of enrichment p value. To enable global
comparison, the grey shade of the letters was scaled the
same way over all plotting windows.
To assess the sensitivity of differential expression
analysis with respect to the number of DMA (=experi-
mental replicates), the following approach was used: For
each condition, we identified the differentially expressed
genes based on five pairs of DMA (control vs treated),
which was then used as the reference list. Significant PS
were identified in all cases by Limma t test, with a p \ 0.05
as significance threshold. The Benjamini–Hochberg and
the Benjamini–Yekutieli were used for the FDR correction
in different experiments as appropriate and as specified in
the figure legends. All possible permutations of 2, 3 or 4
DMA were calculated, and the differentially expressed PS
of all these conditions were identified (using the same
method as for the reference calculation). Finally, the
overlap between the new gene lists and the reference was
calculated, to determine the quantity of the reference that
could be recovered with less DMA.
Results and discussion
Detection of different transcriptional responses
to the DNT model compounds, valproic acid
and methylmercury
To explore the dynamics and specificity of the transcrip-
tional response of novel hESC-based in vitro systems
(Fig. 1), we chose VPA and MeHg as two positive control
toxicants with described effects on DNT and D-mannitol as
the negative control compound. The three test compounds
were initially evaluated in three of the test systems (UKK,
UKN1 and JRC) at the ‘maximum tolerated concentration’.
This benchmark concentration (BMC) was determined
experimentally for each of the test systems as the highest
concentration that reduced overall cell viability by not
more than 10 % (Fig. S1). In the case of mannitol, a large
range of concentrations, from 1 lM to 100 mM, was used
and no cytotoxicity was detected (data not shown). For the
UKN1 system, the response to mannitol was tested by
quantitative PCR for three toxicant-responsive genes
(OCT4, Pax6 and OTX2) (data not shown). As no changes
were observed for concentrations up to 40 mM, and data
on this compound were provided by the other test sys-
tems, DMSO (28 lM) was chosen as the DMA-negative
control for UKN1. The transcriptional alterations trig-
gered by the BMC of the two toxicants (VPA/MeHg) or
by the two negative controls (mannitol/DMSO) were
measured in 4–5 independent experiments on Affymetrix
DMA, and the genes that were differentially expressed
between culture medium-only controls and test com-
pounds were determined by modern stringent statistical
methods (Limma t test, Benjamini–Yekutieli FDR correc-
tion). The complete set of data is displayed in supplementary
Table S1.
For a visual monitoring of the different compound
effects, the hundred most regulated (defined by the lowest
FDR-corrected p values) genes (top 50 for VPA and top 50
for MeHg) were selected for each test system (Table S1),
and their relative expression levels were displayed as heat
maps. For all test systems, striking differences were
observed between the regulation patterns of VPA and
MeHg. Clustering analysis showed that VPA samples were
clearly separated from the MeHg samples (Fig. 2). This
effect was even more pronounced when clustering was
performed with the 100 top genes regulated by VPA (Fig.
S2A). Under these conditions, the differences between
MeHg and negative controls were small or not apparent.
Therefore, clustering was also performed with the top 100
genes regulated by MeHg. Under these conditions, MeHg
samples were clearly separated from those treated with
D-mannitol/DMSO (Fig. S2B).
The number of significantly altered Affymetrix DMA
probe sets (PS) was much higher for VPA compared to
MeHg. The sum of all PS changed by VPA in the test
systems UKK, UKN1 and JRC was 15386; for MeHg, the
sum was 1246 PS (Table S1, Fig. 3). This striking differ-
ence was observed, although both compounds were used at
their respective BMC in each test system. Exposure to the
negative controls did not result in any significant changes
(Fig. 3). Thus, the extent of the responses of the neurally
differentiating hESC to the different developmental neu-
rotoxicants appears to be compound-specific. Moreover,
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the responses to the two model toxicants differed qualita-
tively (Fig. 2; Fig. S2). The ability to clearly distinguish
known toxicants suggests that the test systems would dis-
tinguish unknown classes of potential toxicants. It may be
speculated that safety liabilities of unknown chemicals for
humans may be predicted by comparing their effects in the
test systems with those of known toxicants and non-toxi-
cants. The technical and statistical basis of the above initial
findings, together with their potential biological and toxi-
cological implications was explored further in the follow-
ing extended test battery.
Differential constitutive and toxicant-induced responses
of the test battery
One may hypothesise that MeHg showed only relatively
weak effects in the initial testing (UKK, UKN1 and JRC)
as all these systems only generate immature cells, and such
cells may be relatively resistant to MeHg. Alternatively,
such test systems may lack key targets of mercury toxicity.
Such an assumption would be in agreement with findings in
neuronally differentiating murine ESC, which were highly
sensitive to MeHg during the late neuronal maturation
phase, but relatively insensitive during the initial phase of
neural precursor formation (Zimmer et al. 2011b). For a
broader coverage of effects during later phases of neuro-
genesis, two additional test systems were used (Fig. 1,
UNIGE and UKN4). The UNIGE hESC-based test system
covers the developmental phase after neural stem cell
formation. The UKN4 test system was used as reference, as
this system is well characterised not only for transcriptome
changes, but in particular for functional and phenotypic
effects (Stiegler et al. 2011). From the literature, it is
known that MeHg inhibits neurite outgrowth in this system,
and transcriptome analysis was performed at a concentra-
tion known from previous studies to affect neurites (Stie-
gler et al. 2011).
The extended test battery (UKK, JRC, UKN1, UKN4
and UNIGE) was used for additional testing. The effects of
MeHg were examined in all systems at the respective
BMC, in addition to one lower concentration (LOW). The
latter was determined by dividing the BMC by a factor of
four (Fig. S1). Additional experiments were also performed
with VPA. The compound was tested at two relatively
similar concentrations in JRC (to test the reproducibility of
the response). It was also examined at fourfold different
concentrations in UKK (to test potential concentration
dependencies of the response). The number of differen-
tially expressed PS for each condition is summarised in
Fig. 3. This broad experimental approach showed that the
transcriptional response of differentiating hESC to MeHg is
indeed very limited. Also, the test systems using more mature
cells (UKN4 and UNIGE) did not show any significant
response when stringent FDR corrections were used.
Comparison of the results before and after FDR cor-
rection showed the unmistakeable need for appropriate
JRCUKK UKN1
MeHgVPAMannitol DMSO
Fig. 2 Differential alterations of gene expression by valproic acid
(VPA) and methylmercury (MeHg). Three different test systems
(UKK, UKN1 and JRC) were exposed to VPA (blue label on top of
the heatmap) or MeHg (green label) at their respective benchmark
concentration, or to D-mannitol (red) or DMSO (dark red). The
differentially expressed genes (vs untreated controls) were determined
in 4–5 independent experiments (shown as columns of the heatmaps).
The similarity of the gene expression patterns is indicated by the
Pearson’s distance dendrogram at the top. The heatmaps are based on
100 selected genes. These comprise the 50 genes with the lowest
adjusted p values according to the Limma t test for regulation by
MeHg, and 50 genes with the lowest adjusted p values for VPA. The
colours of the heatmap indicate the relative gene regulation level
above (red) or below (yellow) the average for each row
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statistical treatment of the data. Although the choice of a
5 % significance level will generate on average 2734 false
positives when 54675 PS are analysed (as in this study), it
can at times still be counter-intuitive for toxicologists when
none of the more than 2000 identified genes is significant
after FDR correction. The effect of FDR correction in the
present study is visualized in the form of volcano plots.
This form of display orthogonally separates the two
parameters usually considered important in gene expres-
sion analysis: the fold change and the significance level. As
the FDR correction only affects the significance level, one
can see the ‘volcano’ heights being compressed, while the
width remains the same; for instance, in the case of JRC
incubated with 273 nM MeHg (BMC), all apparently sig-
nificant PS dropped below the usual significance level
(p \ 0.05). Also, with UKK exposed to 500 lM VPA
(20 % of the BMC), the number of 2524 PS that appeared
to be significantly up-regulated before FDR correction
dropped down to four really significant PS after FDR
correction. Notably, the apparent significances were ‘lost’,
although several PS appeared to be ‘regulated’ more than
twofold, at times even up to fourfold (Fig. 4, Fig. S3). It
should be noted that the gene expression response occurred
within a narrow range of concentrations. The FDR-cor-
rected data sets showed that the number of regulated probe
sets can change from several thousands to zero within a
fourfold concentration range. Even a lowering of the test
concentration by only 20 % (relative to the BMC) resulted
in a reduction of the identified PS, at least in one system in
which this was tested (JRC). However, more than 90 % of
the PS identified at the low concentration in this assay were
also identified at the high concentration (Fig. 5). This good
overlap confirmed a robust and reproducible test system
response. When more stringent conditions were used for
filtering, such as the requirement for a C4-fold change or
for a lower p value, the good overlap between the two
concentrations was maintained (Fig. 5). Altogether, these
data suggest that the most pronounced and robust tran-
scriptional responses can be measured at toxicant concen-
trations, which are close to or at the BMC.
To obtain a better overview of how the different test
systems are related to one another, we performed a prin-
cipal component analysis (PCA) encompassing untreated
controls and non-differentiated H9 hESC, in addition to all
treated samples. This approach allowed the visualization of
the overall transcript patterns measured by 190 DMA on a
2-dimensional PCA space (Fig. 6a). Several conclusions
can be drawn from a qualitative analysis of the PCA pre-
sentation: First, all test systems clearly differed from non-
differentiated hESC. Second, all test systems differed from
one another, that is, the variance between the different test
systems was larger than the variance of individual samples
Probe sets JRC UKK UKN1 UKN4 UNIGE
MeHg 273 nM 68 nM 25 nM 1000 nM 250 nM 1500 nM 375 nM 200 nM 50 nM 800 nM 160 nM 40 nM
not 625 605 260 5450 3348 6445 2639 2817 3820 2800 724 1403 
adjusted
↑
↓ 960 621 278 4813 2231 4540 2870 2791 4837 2599 750 1655
adjusted ↑ 0 0 0 407 0 375 0 0 0 0 0 0↓ 0 0 0 420 0 44 0 0 2 0 0 0
VPA 1.21 mM 1.05 mM 2 mM 0.5 mM 0.6 mM
nd nd
not
adjusted
↑ 9542 8882 7881 2524 8450
↓ 9933 9108 8109 1739 9151
adjusted ↑ 3976 2979 2127 4 2164↓ 3817 2754 1765 0 1533
Mannitol 100 mM 1 mM 40 mM
nd nd
0.05 mM 0.001 mM
not
adjusted
↑ 93745140220993402
↓ 07838410249315731
adjusted ↑ 00000
0 0 0 0 0↓
Fig. 3 Overview of differentially expressed genes in all test systems.
Positive and negative control compounds were tested in the JRC,
UKK, UKN1, UKN4 and UNIGE test systems. The test concentra-
tions for methylmercury (MeHg), valproic acid (VPA) and D-man-
nitol (Mannitol) are indicated in the white fields. The number of
significantly altered probe sets (PS) is indicated separately for up-
regulations (red) and down-regulations (blue). The results for testing
without FDR adjustment are indicated in pale-coloured fields. The
results after FDR adjustment by the Benjamini–Yekutieli method are
indicated in white bold numbers. The highest compound concentra-
tion tested corresponded to the BMC of the respective test system.
The highest test concentration (800 nM) was five times higher than
the BMC (160 nM) for UNIGE only. nd not done
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within a given test system. Third, samples from one test
system clustered together, whether they had been treated
with VPA, MeHg or solvent. On the other hand, samples
treated, for example, with MeHg in different test systems
did not cluster together in this form of data presentation. It
is noteworthy, that presentation of data in the form of such
a comprehensive PCA does not allow the identification of
compound effects, although large, statistically significant
transcriptome changes occurred (e.g. VPA vs solvent
control). To better visualise compound effects, a different
statistical treatment is required before the data are pre-
sented; for instance, the large influence of the different test
systems can be attenuated by the subtraction of the corre-
sponding controls before display (see below and Fig. 7).
The distinct clustering of all test systems to a different
area of the PCA plot suggests that the test battery is not
redundant. Each individual test system seems to react with
different transcriptome changes, and the combination of the
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Fig. 4 Correlation of fold
change and significance level of
gene expression for different
statistical approaches. Data
were generated and calculated
for each combination of test
system and compound, as
illustrated in Fig. 3. In the
volcano plot diagrams, fold
changes of the compound-
induced gene expression are
shown on the x-axis (log2-
scale). The y-axis shows
negative logarithmic-adjusted
p values of a LIMMA t test
(-log10(p value)). The p values
were a FDR-adjusted, or b not
FDR-adjusted. The dashed lines
show the significance level of
p = 0.05. The dotted lines show
an example for the
p = 0.000001 significance level
for orientation. All other test
systems and compounds are
shown in the supplemental
material (Fig. S3)
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tests may thus provide richer data than any individual test.
This would imply that the different systems would be able
to identify different toxicant effects and thus be comple-
mentary in their toxicological information. The test battery
may thus constitute an important step towards the
replacement of animal tests by information-rich human
cell-based models (Hartung and Leist 2008; Leist et al.
2008b). This will, however, require further testing and
validation (Leist et al. 2012). A second important obser-
vation was the presence of outliers in some samples, which
will be investigated in greater detail in the following sec-
tion (Fig. 6a).
Control of intra-group variability and batch effects
The PCA indicated that eight of the DMA of UKN1
clustered separately from all other UKN1 samples. The
commonality amongst the eight DMA was that they were
measured on a different day compared to the other samples.
Four corresponded to controls and four to samples treated
with VPA. Thus, the clustering was not treatment-related.
A similar situation was observed for ten samples of UNIGE
(Fig. 6a). When only the 500 probe sets with the highest
variance were considered for the PCA, the ‘outliers’ moved
partially or completely back, that is, they clustered together
with the other samples within their test system (Fig. 6b).
This suggested that genes with a low variance had con-
tributed to the outlier effect. A graphical presentation of the
variances of all DMA performed for this study indeed
indicated that the ‘outliers’ had a higher variance of the
fluorescence signals, although the average signals were
quite similar to all other DMA (Fig. 6c). These data sug-
gest that the ‘distant clustering’ samples are the conse-
quence of a batch effect.
The presented study is still ongoing and even larger
numbers of samples will have to be studied. This makes it
p-value
P ≤ 0.05 P ≤ 0.01JRC (VPA) 
ol = 91% ol = 92%
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low:  1.05 mM
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Fig. 5 Overlap of differentially expressed probe sets (PS) at different
concentrations. The JRC test system was exposed to VPA at a high
(=BMC) and low concentration in five independent experiments. The
circles of the Venn diagrams show the numbers of PS that were
influenced by the two experimental conditions. The overlap gives the
number of genes influenced both at the low and the high concentra-
tion. The fraction of the genes in the overlap (ol) with respect to all
genes altered at the low concentration is indicated above each
diagram. The number at the lower right corners indicates the number
of PS not influenced by the test compound at any concentration.
Significance was determined by the LIMMA FDR-adjusted t test. The
first column shows results without restriction by the p value and
examines the effect of restrictions by the fold-change value on the
number of PS identified. The second column imposes the additional
restriction that all identified PS should have a p value below 0.05. The
third column shows the results when only PS with a p value below
0.01 are selected
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impossible to analyse all samples in a single batch.
Methods to control for batch effects will therefore be
required. As indicated here, one possibility is to include
only the PS with highest variability between the samples
into the analysis. As an alternative approach, the corre-
sponding control values were subtracted from the com-
pound-treated samples before the PCA. This form of
presentation clearly separated VPA and MeHg incubated
samples, and the results obtained by clustering analysis
within the individual test systems were confirmed, also
when this multi-systems approach was chosen (Fig. 7a).
The subtraction of the controls resulted in the visualization
of treatment effects in the PCA that were not visible when
the non-processed data were used (Fig. 6). When only the
500 PS with the highest variance—rather than all 54,575
PS—were included, there was a more defined clustering of
the VPA samples compared to the MeHg samples
(Fig. 7b). The reduction to 500 PS also resulted in a better
clustering of other ‘distant clustering’ samples. A stepwise
reduction of PS showed that 500 PS seems to represent a
reasonable choice, although even smaller numbers, for
example, 200 PS, would be possible (Fig S4). An
JRC UKK UKN1 UKN4 UNIGE
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Fig. 6 Identification and correction of DNA microarray (DMA)
batch effects. The signal of all PS was determined in five different test
systems after incubation with compounds as in Fig. 3. The data for
every experiment plus those of 25 untreated controls and solvent
controls and 21 samples of untreated hESC (dark green circles with
light blue filling) were used for principal component analyses (PCA)
of altogether 190 DMA. Data from the different test systems are
colour-coded, and each DMA is displayed as a circle in the PCA plot.
Circles filled in yellow code for DMA that clustered away from their
respective main groups, and that were considered outliers due to a
batch effect, as they were measured at another time point compared to
the other samples. The axis labels indicate the percentage of the total
variance covered by the respective axis a The PCA is based on all PS.
b The PCA is based only on the 500 probe sets with the highest
variance. c The distribution of the PS fluorescence signals (indicated
here as ‘gene expression value’) is displayed for all 169 test system
DMA of this study (each DMA is represented by one box of the box
plot). The size of the boxes indicates the 25th and 75th percentile (the
lower and upper quartiles, respectively) of the PS. The solid lines in
the box indicate the 50th quantile of the distribution. The height of the
box being equal to the difference between the upper and lower
quartiles is called the interquartile range (IQR). The dashed lines
(whiskers) indicate gene expression values within the range of 1.5
IQR from the 25th and 75th percentile. The dots outside the dashed
lines (appearing as solid line due to the print resolution) represent the
outliers within one DMA. The DMA corresponding to the differently
clustering samples in a is indicated by boxes filled with yellow, and
they show a higher variance. The test system colour coding of part a,
b and c is identical
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interesting implication of this observation is that the scat-
tering of samples within one group can be caused by rel-
atively large numbers of PS with low variability and not
necessarily by the PS which show the highest variance.
These ‘high variance PS’ appear to be highly relevant for
further analysis.
A
PC1 (17 %)
PC2 (10 %)
JRC
PC1 (37 %)
PC2 (18 %)
JRC UKK UKN1
UKN4 UNIGE All Systems
B
MeHg
VPA
Mannitol
DMSO
UKK UKN1
UKN4 UNIGE All Systems
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Robustness analysis: role of the number of biological
replicates
In the present study, five biological replicates (independent
experiments performed at different days) were generated
for most test conditions. One technical replicate (one
DMA) was analysed per experiment. To study whether
lower numbers of DMA would also lead to similar results
in the present data set, we chose a statistical permutation
approach that simulated the situation of choosing only 2, 3
or 4 of the 5 experimental replicates (Note that each rep-
licate consisted of a matched pair of DMA for control and
for treated cells). For each possible combination of these
pairs (here for simplicity called DMA or replicates), the
number of PS that overlapped with the original set of PS
was identified. In addition, new PS that had not been
originally identified were also detected. The expectation
was that whether 5 DMAs were redundant, then the per-
centage of original PS identified with 3 or 4 DMA should
also be high, and the number of new PS arising from the
new analysis should be low. This approach was run under
different conditions. The significant genes were identified
by the less stringent Benjamini–Hochberg FDR correction
(Fig. 8) or by the very stringent Benjamini–Yekutieli cor-
rection (Fig. S5). Moreover, either all PS were considered,
or only the ones regulated more than twofold (Fig. 8, Fig.
S5).
The results showed that there was only a moderate
advantage of using 5 DMA instead of 4 when only PS with
C2-fold changes were considered in the current data set.
Under this condition, and using less stringent FDR cor-
rection, even 3 DMA would have resulted in the identifi-
cation of a large majority of genes. The permutation
analysis was also found to be a suitable tool to test data
consistency and robustness of the analysis method used.
For most test systems, removal of any of the 5 DMA (pairs)
to generate a new data set based on 4 DMA yielded largely
similar results. This suggests that all different experiments
had generated largely similar data, although they were
performed with different cell cultures on different days.
The situation was different for the MeHg samples from
UKN1, where removal of one specific DMA resulted in the
identification of more than twice as many significant PS
compared to the remaining 4 DMA. All combinations of
the three remaining DMA that lacked the apparent ‘outlier’
identified much larger numbers of PS compared to the
combinations that included that specific DMA (pair)
(Fig. 8). Such an analysis may therefore be used to develop
statistical techniques for the identification of outliers.
The relationship between cytotoxic response
and DNT-specific transcriptome changes
The choice of toxicant concentrations for gene expression
analysis is a critical step. If too high concentrations are
used, cell viability will be compromised. The cell death
occurring under these conditions may result in unspecific
‘toxicity-associated’ gene expression responses. Con-
versely, the use of too low concentrations of test com-
pounds would result in false-negative responses and in the
inability to identify any alterations of the transcriptome.
The magnitude of the response may be dependent on the
concentration of the test compound, which is especially
important when compounds are compared and possibly
classified or ranked according to their specific responses.
Furthermore, information on the concentration dependence
may be used for more detailed characterisation of com-
pound effects, and possibly for the identification of the
hazardous responses as opposed to counter-regulations and
unspecific responses (Theunissen et al. 2012a, b).
In the present study, the BMC of the cytotoxicity test
(i.e. the highest non-cytotoxic concentration) was used as
the standard test concentration (Fig S1). Although tran-
scriptional responses can be triggered by MeHg and VPA
at concentrations considerably lower than the cytotoxic
concentration (Balmer et al. 2012; Zimmer et al. 2011b),
we found here that the majority of responses to MeHg in
UKN1 was lost even at only fourfold lower concentrations
than the BMC. We made similar observations for VPA in
other test systems.
In in vivo studies, DNT is defined as effects on the pups
in the absence of maternal toxicity. A corresponding defi-
nition for in vitro test systems would be ‘specific altera-
tions of differentiation in the absence of overt (unspecific)
cytotoxicity’. Fulfilment of this condition was carefully
explored, and several features of our data indicate that
measurements at the BMC do in fact allow us to draw
conclusions on DNT-specific disturbances triggered by the
test compounds: First, we tested whether known toxic
concentrations (800 nM MeHg in UNIGE; BMC was 160
nM) would lead to unspecific transcriptional responses
(Fig. 3). Also under this condition, no significant PS were
Fig. 7 Principal component analysis (PCA) of relative gene expres-
sion data after subtraction of solvent controls. a The signal of all PS
was determined in five different test systems (UKK, UKN1, JRC,
UKN4 and UNIGE) after incubation with compounds as in Fig. 3.
Then, the values for the respective controls were subtracted from the
values of the DMA treated with VPA at the BMC (large blue) or at
the LOW concentration (small blue dots), or MeHg (large and small
green dots), or D-mannitol (red), or DMSO (black). These data were
then used for PCA. The lower right panel shows all data together. The
other panels show the data for individual test systems within the same
axes as for all systems. In a, all PS were included, while in b, only the
500 PS with the highest variance were used. Note for instances, the
outliers in UNIGE marked by arrows in a, and their perfect clustering
in b
b
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identified, that is, no cell death genes were triggered. We
also examined the effect of accidental variations of the
cytotoxicity from experiment to experiment. The fixed
BMC indicated here was determined from a set of pilot
experiments. However, the actual cytotoxicity in the indi-
vidual experiments in which mRNA levels were analysed
showed some biological variation, which was documented,
for example, for UKN1 and UKN4. Examination of these
data showed that the MeHg concentration used for UKN4
reduced cell viability more than the one used for UKN1.
However, no response was observed in UKN4, while an
apparently specific response was triggered in UKN1. Sec-
ond, some concentrations used for testing VPA in UKN1
triggered toxicities of more than 10 % (data not shown) in
the experiments used for DMA analysis (due to daily
experimental variations in sensitivity), but cell death-rela-
ted GO terms were not identified. In contrast, MeHg in the
same system did not trigger measurable cytotoxicity, but
GO term analysis indicated an up-regulation of genes
related to apoptosis and neuronal death. Thus, the use of
compounds at the BMC does not seem to be problematic.
In the case of MeHg, triggering of cytotoxic responses is
rather a specific feature of the compound (protein modifier,
trigger of oxidative stress). This may be an explanation for
the low or absent transcriptional responses in the test sys-
tems. Third, candidate genes typically related to cell death,
DNA damage and oxidative stress were examined in
UKN1. Such genes were not overrepresented amongst the
VPA-regulated genes. Moreover, their extent of regulation
did not correlate with the overall magnitude of regulation
Fig. 8 Simulation of different numbers of experiments (pairs of
DMA) and their impact on the numbers of significantly regulated PS.
VPA was tested in the test systems JRC and UKK at its BMC in five
independent experiments, and in UKN1 in four experiments. MeHg
was tested in UKN1 and UKK in five experiments. The number of
significantly regulated genes (Benjamini–Hochberg FDR correction)
was calculated without further restrictions (left) or with the restric-
tions that the PS should be regulated more than twofold (right). The
numbers of PS are indicated above the dashed black lines, which were
set as 100 % reference points. The dark blue bars indicate how many
of these PS were identified when different permutations of 2, 3 or 4
experiments (indicated as grey headings) were used. The light blue
bars indicate how many additional PS were identified when only
subsets of the original five (4) experiments were analysed; for
instance, the five bars in the panel with the coordinates 4/JRC:VPA
represent the five possible ways of omitting one of the experiments.
The 10 bars in the panel with the coordinates 3/JRC: VPA represent
the 10 possible permutations of leaving out two of the experiments
and then recalculating the significant PS on the basis of the remaining
3 DMA
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in the individual experiments (not shown). Fourth, it was
examined how far the responses to different toxicants
overlapped. In case of a strong component of cytotoxicity,
it was expected that typical stress genes were induced and
similarities would be observed in the regulation pattern of
different toxicants. However, only a small fraction of the
overall altered PS overlapped between VPA and MeHg [as
examined in detail below, (Fig. 10)]. Even though a
‘common transcription factor response’ between VPA and
MeHg of 16 transcription factors (TFs) was observed, there
was still a majority of TFs unique for MeHg or VPA. Thus,
two compounds, both used at the BMC, triggered different
responses, with no common cytotoxicity pattern.
In summary, the data indicate that the measurement of
transcriptional responses at the BMC is a reasonable
approach, although further studies are required for a better
understanding of a possible ‘common toxicity-associated
response’. Our limited set of data indicates that concen-
trations beyond the BMC do not necessarily result in an
unspecific transcriptional response reflecting cytotoxicity.
Relationship of the BMC with respect to the in vivo
relevant concentration range
Besides the technical considerations concerning the BMC
and cytotoxicity, the relevance of the chosen concentra-
tions for the in vivo conditions needs to be considered.
When in vitro concentrations differ by more than one order
of magnitude from concentrations causing toxicity in vivo,
pathways of toxicity may become activated that are not
relevant to the in vivo situation. Unfortunately, human
exposure measurements of DNT compounds are often
poorly documented and concentrations in the brain are only
rarely known. Nevertheless, human relevant concentrations
of 0.005–0.5 lM MeHg and 500–1,000 lM VPA have
been reported in a recently published review (Kadereit
et al. 2012). To obtain a clearer picture, we used physiol-
ogy-based pharmacokinetic (PBPK) modelling to calculate
in vivo relevant blood and brain concentrations from the
doses that caused DNT in animal studies (Fig. 9; Fig.
S6A). Oral exposure to MeHg of 0.01 mg/kg on gestation
days 6–9 is predicted to result in a maximum total blood
concentration of 0.9 lM (Fig. 9a). Thus, similar nominal
concentrations should show activity in vitro, although the
actual amount of MeHg penetrating the cells may addi-
tionally depend on cysteine concentrations in the different
media of the test systems. A VPA plasma peak concen-
tration of 6.6 mM is predicted after a single oral dose of
350 mg/kg. This dose resulted in the same model in DNT
(Rodier et al. 1996) (Fig. 9b). For extrapolation of such
data to in vitro systems, corrections for differences in
protein binding and lipid partitioning in plasma vs cell
culture medium have to be considered (Fig. S6B). Our
calculations suggest that the expected equivalent nominal
concentrations in vitro are 3.3 mM for UKK, 2.7 mM for
UKN1 and 0.9 mM for JRC, UKN4 and UNIGE. These
results show that the BMC concentrations used in this
study are within the same order of magnitude as the in vivo
concentrations which caused DNT in humans and animals.
Remarkable overlap of overrepresented TFBS amongst
genes influenced by VPA and MeHg
The main focus of this study was to investigate the tech-
nical feasibility of using transcriptomics as a major
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Fig. 9 Physiologically based pharmacokinetic (PBPK) modelling of
the positive control compounds MeHg and VPA. Systemic concen-
trations of MeHg (total blood concentration, upper panel) and VPA
(plasma concentration, lower panel) in rats following exposure to a
developmental neurotoxic dose predicted by PBPK modelling.
a PBPK simulation of MeHg total blood concentration in rat dams
upon daily oral gavage of 4 mg/kg MeHg on gestation days 6–9, the
lowest developmentally neurotoxic dose in Bornhausen et al. (1980).
Predicted maximum total blood concentration of 0.9 lM is indicated.
Maternal and foetal blood concentrations are considered similar. The
foetal total blood concentration is assumed to be available for foetal
brain exposure and equated to the nominal concentration in in vitro
test media. b PBPK simulation of VPA plasma concentration in rat
dams upon a bolus intraperitoneal dose of 350 mg/kg, the lowest dose
causing relevant effects in Rodier et al. (1996), resulting in a
predicted maximum total blood concentration of 6.6 mM (as
indicated). Comparable concentrations have been found in maternal
and foetal plasma. The unbound plasma concentration in vivo is
equated to the unbound concentration in in vitro test media
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endpoint to characterise responses of hESC-based test
systems. For a detailed characterisation of the biological
responses of the test systems to the compounds, a different
experimental design would be required. Nevertheless, we
performed some initial comparisons of gene ontologies
(GO) and transcription factor binding sites (TFBS) that
were overrepresented amongst the regulated PS. The main
aim was to find out whether simple analysis tools can
reveal differences and commonalities of the transcriptome
responses.
For this approach, five sets of data were compared: the
responses of UKN1, JRC and UKK to VPA and the
responses of UKN1 and UKK to MeHg (all at BMC con-
centration). To obtain an overview over the main biological
processes affected by co-regulated genes, the statistically
overrepresented GO terms were identified and displayed
for each test system and condition (Fig. S7); for instance,
the genes down-regulated in each test system by VPA
pointed to effects of the toxicant on RNA processing, and
on chromatin modification/histone acetylation. The latter
results are consistent with the known activity of the com-
pound as a histone deacetylase inhibitor (HDACi). GO
terms related to effects on ‘neural tube formation’ ‘neuron
development’ and ‘embryonic morphogenesis’ showed up
for different conditions. These findings gave a hint that
there may be an overlap of higher order biological
responses across the test systems and compounds. How-
ever, we are aware of the fact that the GO term analysis is a
very rough tool, and that GO term annotations of many
genes can be problematic (Weng et al. 2012). Therefore,
we chose the alternative approach of comparing the overlap
of regulated PS between the test systems with the over-
representation of 267 human TFBS (as indirect indicator of
higher order linked biological processes).
First, the overlap of test systems treated with the same
compound was analysed. VPA regulated 571 PS in all three
test systems (Fig. 10a). Thus, only a relatively minor
overlap occurred on the level of individual PS. The PS for
VPA showed enrichment of binding sites for 56 (JRC), 57
(UKK) and 66 (UKN1) TFs. Twenty-five TFBSs over-
lapped between all samples treated with VPA (Fig. 10a),
that is, there was a relatively high overlap of responses on
the level of TFBS. A similar behaviour was observed after
treatment with MeHg: less than 10 % of the PS overlapped
between UKN1 and UKK. Amongst these PS, 46 TFBS
(UKN1) or 44 TFBS (UKK) were overrepresented and out
of these, twenty ([40 %) overlapped (Fig. 10b).
Probe sets TF binding sites
JRC
JRC
UKN1
UKK
UKN1
UKK
4529
1584
1624
1464
1229
273
571
15
15
34
13
3
4
25
39
381 789 26 20 24
UKN1UKN1 UKK UKK
36
3
568 4 16 9
205
A VPA
B MeHg
C JRC, UKK, UKN1
D UKK
MeHg VPA MeHg VPA
MeHg VPA MeHg VPA
622 3687 22 22 35
UKN1
MeHg
277
142
3555 17 29 37
E
VPA MeHg VPA
Fig. 10 Overlap of altered genes and of overrepresented transcription
factor (TF) binding sites between test conditions. Five sets of data, as
described in Fig. 3 were used for further analysis and comparisons:
exposure of UKK and UKN1 to both VPA and MeHg and of JRC to
VPA. All toxicants were used at their BMC. The numbers of
differentially expressed probe sets (Limma t test, Benjamin–Yekuti-
eli-adjusted p value \0.05), and enriched transcription factor (TF)
binding sites (PRIMA, p value \0.05) were identified. The data are
presented as pairs of Venn diagrams, with PS to the left and TFBS to
the right. Numbers on the diagrams show the relevant count for each
sector of the diagram. The following sets of data are compared:
a responses to VPA treatment in the JRC, UKK and UKN1 test
systems; b responses to MeHg treatment in UKK and UKN1 (N.B. for
display rules: 44 TFBS were changed in UKK, 20 of which
overlapped with UKN1); c the circles marked ‘VPA’ show the
number of PS/TFBS regulated in all three test systems by VPA, the
circles marked ‘MeHg’ show the number of features co-regulated in
UKN1 and UKK by MeHg; d responses of UKK alone to MeHg or
VPA; e responses of UKN1 to MeHg and VPA
b
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In view of these findings, it was interesting to look at an
overlap of transcriptome changes common to each of the
toxicants in all test systems. We identified the PS and
TFBS jointly modified in all three test systems by VPA or
in UKN1 and UKK by MeHg. Only 3 (0.5 %) of the PS
generally altered by VPA were also significantly affected
by MeHg (Fig. 10c). In contrast, more than 50 % of all
TFBS common to MeHg or VPA overlapped also between
the two compounds (Fig. 10c). The large overlap of com-
monly enriched TFBS between all test systems and com-
pounds provides evidence for the existence of a set of
‘common transcription factors’ (including, e.g., E2F, ETF,
SP1 and AP-2 (Fig. S8). The only TFBS enriched by all
VPA treatments, but not MeHg, was the homeobox gene
Hmx3 (also known as NKX5.1). The only TFBS enriched
by all MeHg treatments, but not VPA, was the one for
GCM transcriptional regulators (Fig. S8).
Similar comparisons of compound responses were also
performed in individual test systems; for instance, in UKK,
only 205 PS of the 3,892 PS regulated by VPA overlapped
with those affected by MeHg (Fig. 10d). On the level of
TFBS, the overlap was much larger, as 22 of the 57 TFBS
enriched in the genes regulated by VPA, were also found
for MeHg (Fig. S9A).
Treatment of the UKN1 test system with VPA or MeHg
resulted in the regulation of genes associated with 66 TFBS
in their promoter in the case of VPA and 46 TFBS in the
case of MeHg. Of these, 29 (comprising, e.g., AP-2, EGR,
STAT1, HIF-1, AhR and Sp1) were similar for both com-
pounds, 37 (comprising, e.g., HSF-1, IRF-1, PAX5 and
NKX2-5) were specific for VPA, and 17 (comprising, e.g.,
ATF4, HOXA4 and ZIC2) specific for MeHg (Fig. S9B).
Again, the overlap of TFBS was much larger than the one of
individual PS. Only 142 of the 3,697 genes regulated by
VPA overlapped with those affected by MeHg (Fig. 10e).
Besides the commonly regulated TFBS, we found for
each compound also TFBS that were specific for the test
system and the chemical used. These may be used as sig-
natures for related chemicals within one class, while the
commonly affected TFBS may give a general indication of
toxicity (Supplementary Table S2). In conclusion, a
remarkable observation of the present study is that the
TFBS showed an astonishingly large overlap in view of the
very small overlap on the level of the individual genes.
Analysis of further compounds is required to determine
whether the emerging concept of a ‘common toxic response
TFBS’ and a ‘compound-specific TFBS’ is universal.
Acknowledgments This study was funded by the FP7 project
ESNATS, the DFG and the Doerenkamp-Zbinden Foundation. We
thank Sara Skogsater (ARTTIC) for excellent work in coordinating
the ESNATS consortium and for her helpful and professional support
of the current study. The great technical assistance of Marion Kapitza
is gratefully acknowledged.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
Adler S, Basketter D, Creton S et al (2011) Alternative (non-animal)
methods for cosmetics testing: current status and future
prospects-2010. Arch Toxicol 85(5):367–485
Aschner M, Syversen T, Souza DO, Rocha JB, Farina M (2007)
Involvement of glutamate and reactive oxygen species in methyl-
mercury neurotoxicity. Braz J Med Biol Res 40(3):285–291
Bakir F, Damluji SF, Amin-Zaki L et al (1973) Methylmercury
poisoning in Iraq. Science 181(4096):230–241
Balmer NV, Weng MK, Zimmer B et al (2012) Epigenetic changes
and disturbed neural development in a human embryonic stem
cell-based model relating to the fetal valproate syndrome. Hum
Mol Genet 21(18):4104–4114
Barberi T, Klivenyi P, Calingasan NY et al (2003) Neural subtype
specification of fertilization and nuclear transfer embryonic stem
cells and application in parkinsonian mice. Nat Biotechnol
21(10):1200–1207
Basketter DA, Clewell H, Kimber I et al (2012) A roadmap for the
development of alternative (non-animal) methods for systemic
toxicity testing—t4 report*. ALTEX 29(1):3–91
Binkerd PE, Rowland JM, Nau H, Hendrickx AG (1988) Evaluation
of valproic acid (VPA) developmental toxicity and pharmaco-
kinetics in Sprague-Dawley rats. Fundam Appl Toxicol
11(3):485–493
Bornhausen M, Musch HR, Greim H (1980) Operant behavior
performance changes in rats after prenatal methylmercury
exposure. Toxicol Appl Pharmacol 56(3):305–310
Carrier G, Brunet RC, Caza M, Bouchard M (2001) A toxicokinetic
model for predicting the tissue distribution and elimination of
organic and inorganic mercury following exposure to methyl
mercury in animals and humans. I. Development and validation
of the model using experimental data in rats. Toxicol Appl
Pharmacol 171(1):38–49
Castoldi AF, Onishchenko N, Johansson C et al (2008) Neurodevel-
opmental toxicity of methylmercury: Laboratory animal data and
their contribution to human risk assessment. Regul Toxicol
Pharmacol 51(2):215–229
Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain
M, Studer L (2009) Highly efficient neural conversion of human
ES and iPS cells by dual inhibition of SMAD signaling. Nat
Biotechnol 27(3):275–280
Chen PS, Wang CC, Bortner CD et al (2007) Valproic acid and other
histone deacetylase inhibitors induce microglial apoptosis and
attenuate lipopolysaccharide-induced dopaminergic neurotox-
icity. Neuroscience 149(1):203–212
Choi BH (1989) The effects of methylmercury on the developing
brain. Prog Neurobiol 32(6):447–470
Chow S, Rodgers P (2005) Extended abstract: constructing area-
proportional Venn and Euler diagrams with three circles. Paper
presented at the Euler diagrams workshop 2005, Paris
Davidson PW, Myers GJ, Weiss B (2004) Mercury exposure and
child development outcomes. Pediatrics 113(4 Suppl):1023–
1029
Ekino S, Susa M, Ninomiya T, Imamura K, Kitamura T (2007)
Minamata disease revisited: an update on the acute and chronic
manifestations of methyl mercury poisoning. J Neurol Sci
262(1–2):131–144
Arch Toxicol (2013) 87:123–143 141
123
Elkon R, Linhart C, Sharan R, Shamir R, Shiloh Y (2003) Genome-
wide in silico identification of transcriptional regulators control-
ling the cell cycle in human cells. Genome Res 13(5):773–780
Forsby A, Blaauboer B (2007) Integration of in vitro neurotoxicity
data with biokinetic modelling for the estimation of in vivo
neurotoxicity. Hum Exp Toxicol 26(4):333–338
Gaspar JA, Doss MX, Winkler J et al (2012) Gene expression
signatures defining fundamental biological processes in plurip-
otent, early, and late differentiated embryonic stem cells. Stem
Cells Dev 21(13):2471–2484
Grandjean P, Herz KT (2011) Methylmercury and brain development:
imprecision and underestimation of developmental neurotoxicity
in humans. Mt Sinai J Med 78(1):107–118
Grandjean P, Landrigan PJ (2006) Developmental neurotoxicity of
industrial chemicals. Lancet 368(9553):2167–2178
Gray DG (1995) A physiologically based pharmacokinetic model for
methyl mercury in the pregnant rat and fetus. Toxicol Appl
Pharmacol 132(1):91–102
Gulden M, Seibert H (2003) In vitro-in vivo extrapolation: estimation
of human serum concentrations of chemicals equivalent to
cytotoxic concentrations in vitro. Toxicology 189(3):211–222
Harada M (1995) Minamata disease: methylmercury poisoning in
Japan caused by environmental pollution. Crit Rev Toxicol
25(1):1–24
Harbron C, Chang KM, South MC (2007) RefPlus: an R package
extending the RMA Algorithm. Bioinformatics 23(18):2493–
2494
Hartung T, Leist M (2008) Food for thought… on the evolution of
toxicology and the phasing out of animal testing. ALTEX
25(2):91–102
Ingram JL, Peckham SM, Tisdale B, Rodier PM (2000) Prenatal
exposure of rats to valproic acid reproduces the cerebellar
anomalies associated with autism. Neurotoxicol Teratol 22(3):
319–324
Irizarry RA, Hobbs B, Collin F et al (2003) Exploration, normali-
zation, and summaries of high density oligonucleotide array
probe level data. Biostatistics 4(2):249–264
Jagtap S, Meganathan K, Gaspar J et al (2011) Cytosine arabinoside
induces ectoderm and inhibits mesoderm expression in human
embryonic stem cells during multilineage differentiation. Br J
Pharmacol 162(8):1743–1756
Jergil M, Kultima K, Gustafson AL, Dencker L, Stigson M (2009)
Valproic acid-induced deregulation in vitro of genes associated
in vivo with neural tube defects. Toxicol Sci 108(1):132–148
Kadereit S, Zimmer B, van Thriel C, Hengstler JG, Leist M (2012)
Compound selection for in vitro modeling of developmental
neurotoxicity. Front Biosci 17:2442–2460
Klaassen CD (ed) (2010) Casarett and Doull’s toxicology: the basic
science of poisons, 7th edn. McGraw-Hill, New York
Kobayashi S, Takai K, Iga T, Hanano M (1991) Pharmacokinetic
analysis of the disposition of valproate in pregnant rats. Drug
Metab Dispos 19(5):972–976
Kuegler PB, Zimmer B, Waldmann T et al (2010) Markers of murine
embryonic and neural stem cells, neurons and astrocytes:
reference points for developmental neurotoxicity testing. AL-
TEX 27(1):17–42
Kuegler PB, Baumann BA, Zimmer B et al (2012) GFAP-independent
inflammatory competence and trophic functions of astrocytes
generated from murine embryonic stem cells. Glia 60(2):
218–228
Leist M, Bremer S, Brundin P et al (2008a) The biological and ethical
basis of the use of human embryonic stem cells for in vitro test
systems or cell therapy. ALTEX 25(3):163–190
Leist M, Hartung T, Nicotera P (2008b) The dawning of a new age of
toxicology. ALTEX 25(2):103–114
Leist M, Efremova L, Karreman C (2010) Food for thought…
considerations and guidelines for basic test method descriptions
in toxicology. ALTEX 27(4):309–317
Leist M, Hasiwa N, Daneshian M, Hartung T (2012) Validation and
quality control of replacement alternatives—current status and
future challenges. Toxicol Res 1:8–22
Loscher W (1978) Serum protein binding and pharmacokinetics of
valproate in man, dog, rat and mouse. J Pharmacol Exp Ther
204(2):255–261
Louisse J, de Jong E, van de Sandt JJ et al (2010) The use of in vitro
toxicity data and physiologically based kinetic modeling to
predict dose-response curves for in vivo developmental toxicity
of glycol ethers in rat and man. Toxicol Sci 118(2):470–484
Makris SL, Raffaele K, Allen S et al (2009) A retrospective
performance assessment of the developmental neurotoxicity
study in support of OECD test guideline 426. Environ Health
Perspect 117(1):17–25
Meganathan K, Jagtap S, Wagh V et al (2012) Identification of
Thalidomide-Specific Transcriptomics and Proteomics Signa-
tures during Differentiation of Human Embryonic Stem Cells.
PLoS One 7(8):e44228
R_Development_Core_Team (2011) A language and environment for
statistical computing. R Foundation for Statistical Computing,
Vienna
Reimand J, Kull M, Peterson H, Hansen J, Vilo J (2007) g:Profiler–a web-
based toolset for functional profiling of gene lists from large-scale
experiments. Nucleic Acids Res 35(Web Server issue):W193–W200
Robinson JF, Theunissen PT, van Dartel DA, Pennings JL, Faustman
EM, Piersma AH (2011) Comparison of MeHg-induced toxic-
ogenomic responses across in vivo and in vitro models used in
developmental toxicology. Reprod Toxicol 32(2):180–188
Rodier PM, Ingram JL, Tisdale B, Nelson S, Romano J (1996)
Embryological origin for autism: developmental anomalies of
the cranial nerve motor nuclei. J Comp Neurol 370(2):247–261
Rotroff DM, Wetmore BA, Dix DJ et al (2010) Incorporating human
dosimetry and exposure into high-throughput in vitro toxicity
screening. Toxicol Sci 117(2):348–358
Schmidt M, Bohm D, von Torne C et al (2008) The humoral immune
system has a key prognostic impact in node-negative breast
cancer. Cancer Res 68(13):5405–5413
Schmidt M, Hellwig B, Hammad S et al (2012) A comprehensive
analysis of human gene expression profiles identifies stromal
immunoglobulin kappa C as a compatible prognostic marker in
human solid tumors. Clin Cancer Res 18(9):2695–2703
Scholz D, Poltl D, Genewsky A et al (2011) Rapid, complete and
large-scale generation of post-mitotic neurons from the human
LUHMES cell line. J Neurochem 119(5):957–971
Seiler A, Oelgeschlager M, Liebsch M et al (2011) Developmental
toxicity testing in the 21st century: the sword of Damocles
shattered by embryonic stem cell assays? Arch Toxicol
85(11):1361–1372
Shannon P, Markiel A, Ozier O et al (2003) Cytoscape: a software
environment for integrated models of biomolecular interaction
networks. Genome Res 13(11):2498–2504
Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T (2011)
Cytoscape 2.8: new features for data integration and network
visualization. Bioinformatics 27(3):431–432
Smyth GK, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W
(2005) Limma: linear models for microarray data. Bioinformat-
ics and Computational Biology Solutions using R and Biocon-
ductor, Springer, New York, pp 397–420
Stiegler NV, Krug AK, Matt F, Leist M (2011) Assessment of
chemical-induced impairment of human neurite outgrowth by
multiparametric live cell imaging in high-density cultures.
Toxicol Sci 121(1):73–87
142 Arch Toxicol (2013) 87:123–143
123
Stummann TC, Hareng L, Bremer S (2009) Hazard assessment of
methylmercury toxicity to neuronal induction in embryogenesis
using human embryonic stem cells. Toxicology 257(3):117–126
Theunissen PT, Robinson JF, Pennings JL et al (2012a) Transcrip-
tomic concentration-response evaluation of valproic acid, cyp-
roconazole, and hexaconazole in the neural embryonic stem cell
test (ESTn). Toxicol Sci 125(2):430–438
Theunissen PT, Robinson JF, Pennings JL, van Herwijnen MH,
Kleinjans JC, Piersma AH (2012b) Compound-specific effects of
diverse neurodevelopmental toxicants on global gene expression
in the neural embryonic stem cell test (ESTn). Toxicol Appl
Pharmacol 262(3):330–340
Ulitsky I, Maron-Katz A, Shavit S et al (2010) Expander: from
expression microarrays to networks and functions. Nat Protoc
5(2):303–322
van Thriel C, Westerink RH, Beste C, Bale AS, Lein PJ, Leist M
(2012) Translating neurobehavioural endpoints of developmental
neurotoxicity tests into in vitro assays and readouts. Neurotox-
icology 33(4):911–924
Verwei M, van Burgsteden JA, Krul CA, van de Sandt JJ, Freidig AP
(2006) Prediction of in vivo embryotoxic effect levels with a
combination of in vitro studies and PBPK modelling. Toxicol
Lett 165(1):79–87
Wang C, Luan Z, Yang Y, Wang Z, Cui Y, Gu G (2011) Valproic acid
induces apoptosis in differentiating hippocampal neurons by the
release of tumor necrosis factor-alpha from activated astrocytes.
Neurosci Lett 497(2):122–127
Weng MK, Zimmer B, Poltl D et al (2012) Extensive transcriptional
regulation of chromatin modifiers during human neurodevelop-
ment. PLoS One 7(5):e36708
Werler MM, Ahrens KA, Bosco JL et al (2011) Use of antiepileptic
medications in pregnancy in relation to risks of birth defects.
Ann Epidemiol 21(11):842–850
Wetmore BA, Wambaugh JF, Ferguson SS et al (2012) Integration of
dosimetry, exposure, and high-throughput screening data in
chemical toxicity assessment. Toxicol Sci 125(1):157–174
Zimmer B, Kuegler PB, Baudis B et al (2011a) Coordinated waves of
gene expression during neuronal differentiation of embryonic
stem cells as basis for novel approaches to developmental
neurotoxicity testing. Cell Death Differ 18(3):383–395
Zimmer B, Schildknecht S, Kuegler PB, Tanavde V, Kadereit S, Leist
M (2011b) Sensitivity of dopaminergic neuron differentiation
from stem cells to chronic low-dose methylmercury exposure.
Toxicol Sci 121(2):357–367
Zimmer B, Lee G, Balmer NV et al (2012) Evaluation of develop-
mental toxicants and signaling pathways in a functional test
based on the migration of human neural crest cells. Environ
Health Perspect 120(8):1116–1122
Arch Toxicol (2013) 87:123–143 143
123
